Quarterly results and dividend announcement set fresh context for U.S. Physical Therapy

U.S. Physical Therapy (USPH) reported first quarter 2026 revenue of US$198.29 million, compared with US$183.79 million a year earlier. Net income was US$5.04 million, versus US$9.9 million in the prior-year period, alongside a reaffirmed quarterly dividend.

The earnings release appears to have reset expectations, with the stock’s 1 day share price return of 19.9% decline, 30 day return of 21.2% decline and 1 year total shareholder return of 14.8% decline pointing to fading momentum despite revenue growth.

If this earnings reaction has you reassessing healthcare exposure, it may be a moment to look at other opportunities using the 35 healthcare AI stocks

With the share price under pressure and the stock trading at what looks like a steep discount to analyst targets and some intrinsic value estimates, you have to ask: is this a reset that creates a buying opportunity, or is the market already pricing in future growth?

Price-to-earnings of 117.2x: Is it justified?

On simple earnings terms, U.S. Physical Therapy does not look cheap, with a P/E of 117.2x at a last close of $59 and weaker recent profit trends.

The P/E ratio compares the current share price to earnings per share, so a higher figure usually reflects either strong current profitability or confidence in future earnings. In this case, earnings have declined 9.4% per year over the past 5 years and profit margins are described as 1% versus 4.7% a year ago, which suggests the rich multiple is not backed by recent profit delivery.

Against peers, the contrast is sharp. The stock’s 117.2x P/E is well above the peer average of 16.7x and also far ahead of the broader US Healthcare industry average of 22.4x. It also sits meaningfully above an estimated fair P/E of 43.9x, a level the market could move toward if expectations cool or earnings do not catch up.

Result: Price-to-earnings of 117.2x (OVERVALUED)

However, you still have to weigh ongoing margin pressure and the risk that recent share price declines signal deeper concerns about earnings quality or growth expectations.

Another view: DCF suggests a very different story

While the P/E of 117.2x makes U.S. Physical Therapy look expensive on earnings, our DCF model indicates an estimated future cash flow value of $155.63 per share versus the current $59 price. That gap suggests investors are weighing two very different narratives. Which one do you trust?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out U.S. Physical Therapy for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

This mix of risks and rewards can feel conflicting, so do not wait on others to decide what it means for you. Take a moment to review the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop your research here, you might miss stocks that better fit your goals. Use the screener to find ideas that match your risk and return preferences.

• Spot potential mispriced opportunities early by scanning 51 high quality undervalued stocks that combine quality with appealing price tags.
• Lock in more dependable income streams by focusing on 12 dividend fortresses that aim to maintain payouts above 5%.
• Sleep easier at night by concentrating on 71 resilient stocks with low risk scores that score well on resilience and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.